437 | Bexobrutideg (Nx?5948), a Novel Btk Degrader, shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Waldenstr謒 Macroglobulinemia
No Thumbnail Available
All Authors
Lewis,D.
El?Sharkawi,D.
Pulles,A.
Omer,Z.
Munir,T.
Collins,G. P.
Linton,K.
Alencar,A.
Gleeson,M.
McKay,P.
LTHT Author
Munir, Talha
LTHT Department
Oncology
Haematology
Haematology
Non Medic
Publication Date
2025
Item Type
Article
Language
Subject
Subject Headings
Abstract
Journal
Hematological oncology